|Bid||44.10 x 0|
|Ask||46.90 x 0|
|Day's range||44.55 - 46.59|
|52-week range||42.00 - 125.00|
|Beta (5Y monthly)||1.08|
|PE ratio (TTM)||N/A|
|Earnings date||14 Jun 2021 - 18 Jun 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||175.00|
OXFORD, England, August 31, 2021--Oxford BioDynamics awarded FNIH PACT Grant to use EpiSwitch to predict patient response to Immune Checkpoint Inhibitors from a routine blood sample.
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Oxford BioDynamics Plc (AIM: OBD, the Company), a biotechnology company developing personalized medicine tests based on 3D genomics, has entered into a strategic partnership with Boca Biolistics, a US-based biorepository, reference lab and Contract Research Organization (CRO).